CN115335405A - 全人源抗人cd22的嵌合抗原受体及其应用 - Google Patents

全人源抗人cd22的嵌合抗原受体及其应用 Download PDF

Info

Publication number
CN115335405A
CN115335405A CN202180024637.2A CN202180024637A CN115335405A CN 115335405 A CN115335405 A CN 115335405A CN 202180024637 A CN202180024637 A CN 202180024637A CN 115335405 A CN115335405 A CN 115335405A
Authority
CN
China
Prior art keywords
seq
sequence
sequence shown
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180024637.2A
Other languages
English (en)
Other versions
CN115335405B (zh
Inventor
胡广
杨永坤
牛盼盼
孟广荣
程伟
莫家露
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Iaso Biotherapeutics Technology Co ltd
Original Assignee
Nanjing Iaso Biotherapeutics Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Iaso Biotherapeutics Technology Co ltd filed Critical Nanjing Iaso Biotherapeutics Technology Co ltd
Publication of CN115335405A publication Critical patent/CN115335405A/zh
Application granted granted Critical
Publication of CN115335405B publication Critical patent/CN115335405B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)

Abstract

本发明提供了抗CD22抗体分子以及利用该抗CD22抗体分子构建的靶向CD22的嵌合抗原受体(CAR)。本发明还提供了该抗CD22抗体分子和该嵌合抗原受体在制备治疗CD22相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (34)

  1. PCT国内申请，权利要求书已公开。
CN202180024637.2A 2020-04-02 2021-04-02 全人源抗人cd22的嵌合抗原受体及其应用 Active CN115335405B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010254388 2020-04-02
CN2020102543883 2020-04-02
PCT/CN2021/085330 WO2021197483A1 (zh) 2020-04-02 2021-04-02 全人源抗人cd22的嵌合抗原受体及其应用

Publications (2)

Publication Number Publication Date
CN115335405A true CN115335405A (zh) 2022-11-11
CN115335405B CN115335405B (zh) 2024-02-23

Family

ID=77927823

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024637.2A Active CN115335405B (zh) 2020-04-02 2021-04-02 全人源抗人cd22的嵌合抗原受体及其应用

Country Status (8)

Country Link
US (1) US20230174654A1 (zh)
EP (1) EP4130040A4 (zh)
JP (1) JP2023521635A (zh)
KR (1) KR20220163962A (zh)
CN (1) CN115335405B (zh)
AU (1) AU2021250615A1 (zh)
CA (1) CA3177230A1 (zh)
WO (1) WO2021197483A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124109A1 (en) * 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
CN107312091A (zh) * 2017-05-02 2017-11-03 重庆精准生物技术有限公司 靶向人cd19抗原的人源化单克隆抗体
CN107964549A (zh) * 2016-10-20 2018-04-27 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
CN109836495A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd22的单链抗体、嵌合抗原受体t细胞及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
SG177168A1 (en) * 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
WO2013059593A1 (en) * 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
CA2871764A1 (en) * 2012-04-26 2013-10-31 Gerhard Frey Anti-cd22 antibodies
CN109957018A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向cd22的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
AU2019245285A1 (en) * 2018-03-30 2020-11-12 Eureka Therapeutics, Inc. Constructs targeting CD22 and uses thereof
US11939377B2 (en) * 2018-07-12 2024-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
CN109517799B (zh) * 2018-11-30 2022-07-26 北京美康基免生物科技有限公司 一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009124109A1 (en) * 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
CN107964549A (zh) * 2016-10-20 2018-04-27 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
CN107312091A (zh) * 2017-05-02 2017-11-03 重庆精准生物技术有限公司 靶向人cd19抗原的人源化单克隆抗体
CN109836495A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd22的单链抗体、嵌合抗原受体t细胞及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADRIENNE H LONG等: "Lessons learned from a highly-active CD22-specific chimeric antigen receptor", 《ONCOIMMUNOLOGY》, vol. 2, no. 4, 1 April 2013 (2013-04-01), pages 23621, XP009173972, DOI: 10.4161/onci.23621 *
HIND RAFEI等: "Recent advances in the treatment of acute lymphoblastic leukemia", 《LEUKEMIA & LYMPHOMA》, vol. 60, no. 11, 16 May 2019 (2019-05-16), pages 2606 - 2621 *
JÜRGEN KRAUSS等: "Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment", 《PROTEIN ENGINEERING》, vol. 16, no. 10, 31 October 2003 (2003-10-31), pages 753 - 759, XP002422472 *

Also Published As

Publication number Publication date
AU2021250615A1 (en) 2022-12-01
CN115335405B (zh) 2024-02-23
EP4130040A4 (en) 2024-05-01
CA3177230A1 (en) 2021-10-07
JP2023521635A (ja) 2023-05-25
US20230174654A1 (en) 2023-06-08
WO2021197483A1 (zh) 2021-10-07
EP4130040A1 (en) 2023-02-08
KR20220163962A (ko) 2022-12-12

Similar Documents

Publication Publication Date Title
JP7047172B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
JP6884709B2 (ja) 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系
CN105392888B (zh) 使用人源化抗cd19嵌合抗原受体治疗癌症
JP2021525509A (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
US20220017625A1 (en) Tumor-specific anti-egfr antibody and application thereof
CN104780939B (zh) 用于细胞免疫治疗的方法和组合物
CN110177803A (zh) 用于使用融合蛋白进行tcr重新编程的组合物和方法
KR20190101979A (ko) 합성 면역 수용체 및 이의 사용 방법
KR20200015713A (ko) 항-trbc1 항원 결합 도메인
KR20210118426A (ko) 양자 세포 요법을 위한 표적화된 공자극을 제공하는 수용체
EP3875484A1 (en) Cll1-targeting antibody and application thereof
JP2021532742A (ja) Ｎｅｆを含むｔ細胞及びその生成方法
KR20230129979A (ko) 수지상 세포 활성화 키메라 항원 수용체 및 이의 용도
CN115052902A (zh) 淋巴细胞-抗原提呈细胞共刺激因子及其应用
CN115135344A (zh) 在疗法中使用的抗体
CN112739721B (zh) 一种单域抗体及包含抗体结构的嵌合抗原受体
WO2022257984A1 (zh) 一种增强型嵌合抗原受体(car)细胞的制备及其应用
WO2023024084A1 (zh) 一种嵌合抗原受体及其用途
WO2021135178A1 (zh) 一种增强型t细胞受体star及其应用
CN115335405B (zh) 全人源抗人cd22的嵌合抗原受体及其应用
WO2024060140A1 (zh) EGFRvIII嵌合抗原受体及其用途
US20240058447A1 (en) Use of fusion constructs for il-2 independent t cell therapy
TWI840351B (zh) T細胞受體及表現其之工程化細胞
WO2022083590A1 (zh) 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法
CN115368472A (zh) 靶向gd2的嵌合受体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40079524

Country of ref document: HK

CB02 Change of applicant information

Address after: 210061 10th floor, building D, phase II, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Reindeer Biotechnology Co.,Ltd.

Address before: 210061 10th floor, building D, phase II, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: NANJING IASO BIOTHERAPEUTICS TECHNOLOGY Co.,Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant